Back to top
more

AnaptysBio (ANAB)

(Delayed Data from NSDQ)

$21.03 USD

21.03
1,049,965

+0.66 (3.24%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $21.02 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

by Zacks Equity Research

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -266.67% and 5.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks Equity Research

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs

by Zacks Equity Research

MOH expects total membership to be at 5.9 million by 2025-end.

Zacks Equity Research

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

by Zacks Equity Research

Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Zacks Equity Research

GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer

by Zacks Equity Research

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Zacks Equity Research

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

by Zacks Equity Research

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

by Zacks Equity Research

Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Zacks Equity Research

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

by Zacks Equity Research

GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.

Zacks Equity Research

GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli

by Zacks Equity Research

The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.

Zacks Equity Research

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

by Zacks Equity Research

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Zacks Equity Research

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

by Zacks Equity Research

Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Zacks Equity Research

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

by Zacks Equity Research

The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of 33.72% and 279.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio (ANAB) delivered earnings and revenue surprises of -42.50% and 57.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.